Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, August 16, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, August 15, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Kelsey Goodwin Maintained (TSVT) at Strong Buy with Decreased Target to $26 on, Aug 15th, 2023
Kelsey Goodwin of Guggenheim, Maintained "2seventy bio, Inc." (TSVT) at Strong Buy with Decreased Target from $27 to $26 on, Aug 15th, 2023.
Kelsey has made no other calls on TSVT in the last 4 months.
There are 2 other peers that have a rating on TSVT. Out of the 2 peers that are also analyzing TSVT, 1 agrees with Kelsey's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $13 on, Friday, July 28th, 2023
This is the rating of the analyst that currently disagrees with Kelsey
- David Nierengarten of "Wedbush" Maintained at Buy with Decreased Target to $22 on, Friday, July 28th, 2023
